HK Stock Market Move | Jiangsu Hengrui Pharmaceuticals (01276) rose nearly 4%, with net profit attributable to shareholders increasing by 24.5% year-on-year in the first three quarters. Its self-developed hypoglycemic drug, Relettang, has been approved for listing.

Jiangsu Hengrui Pharmaceuticals (01276) rose nearly 4%, as of the time of writing, up 3.76% to HK$23.16, with a turnover of HK$504.121 million. On the news front, on October 27, Jiangsu Hengrui Pharmaceuticals released its performance for the first three quarters of 2025. The group achieved operating income of HK$23.188 billion, a year-on-year increase of 14.85%; net profit attributable to shareholders of listed companies was HK$5.751 billion, an increase of 24.5%; and basic earnings per share were HK$0.89. In addition, according to the official website of Jiangsu Hengrui Pharmaceuticals, recently, its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received a notice from the National Medical Products Administration approving the listing of self-developed slow-release metformin hydrochloride tablets (I) and (II) (Ralentin) for the treatment of adults with type 2 diabetes mellitus with poor blood sugar control. This product, in combination with diet control and exercise, is used to improve blood sugar control. It is worth noting that Ralentin is China's first self-developed oral hypoglycemic triple combination formulation, marking a significant innovative breakthrough in the field of diabetes treatment in China.